TARGET and Allergan partner on ongoing NASH study Home News TARGET and Allergan partner on ongoing NASH study TARGET is pleased to announce a partnership with Allergan on TARGET-NASH, a five-year longitudinal observational study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and childrenhttps://www.healio.com/hepatology/steatohepatitis-metabolic-liver-disease/news/online/%7B055f6de1-77e3-4ad8-a879-d690e871707a%7D/allergan-target-pharmasolutions-partner-on-ongoing-nash-study FacebookTweetPin Related Posts Novartis partners with TARGET PharmaSolutionsNovartis and TARGET PharmaSolutions have entered a long-term strategic alliance for TARGET-NASH Boehringer Ingelheim partners with TARGET PharmaSolutionsBoehringer Ingelheim and TARGET PharmaSolutions will partner together to help progress NASH research Intercept extends strategic partnership with TARGET PharmaSolutionsIntercept and TARGET have recently agreed to extend its strategic partnership revolving around the TARGET-NASH…
